A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Beijing Biotech
IDEAYA Biosciences
AstraZeneca
SpringWorks Therapeutics, Inc.
MedImmune LLC
A2 Biotherapeutics Inc.
InSilico Medicine Hong Kong Limited
Verismo Therapeutics
Bristol-Myers Squibb
TYK Medicines, Inc
CRISPR Therapeutics
Stella Pharma Corporation
Sanofi
Nurix Therapeutics, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Context Therapeutics Inc.
Numab Therapeutics AG
Telix Pharmaceuticals (Innovations) Pty Limited
Medicenna Therapeutics, Inc.
Oncovir, Inc.
Ascentage Pharma Group Inc.
Ferring Ventures Limited
Novartis
Checkpoint Therapeutics, Inc.
BerGenBio ASA
Aminex Therapeutics, Inc.
Suzhou Maximum Bio-tech Co., Ltd.
Ikena Oncology
Sellas Life Sciences Group
UTC Therapeutics Inc.
Prelude Therapeutics
Mateon Therapeutics
Verastem, Inc.
RS Oncology LLC
Multitude Therapeutics Inc.
Polaris Group
Seagen Inc.
Bayer
Mabpro, a.s.
Quadriga Biosciences, Inc.
ImmVira Pharma Co. Ltd
Morphotek
Momotaro-Gene Inc.
Sumitomo Pharma Co., Ltd.
Eli Lilly and Company
CanBas Co. Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Novartis